KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Work In Process: 2018-2024

Historic Work In Process for Acadia Pharmaceuticals (ACAD) over the last 7 years, with Dec 2024 value amounting to $69.7 million.

  • Acadia Pharmaceuticals' Work In Process rose 199.19% to $76.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.9 million, marking a year-over-year increase of 199.19%. This contributed to the annual value of $69.7 million for FY2024, which is 1406.94% up from last year.
  • According to the latest figures from FY2024, Acadia Pharmaceuticals' Work In Process is $69.7 million, which was up 1,406.94% from $4.6 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Work In Process ranged from a high of $69.7 million in FY2024 and a low of $4.6 million during FY2023.
  • Moreover, its 3-year median value for Work In Process was $4.9 million (2022), whereas its average is $26.4 million.
  • In the last 5 years, Acadia Pharmaceuticals' Work In Process fell by 27.24% in 2022 and then surged by 1,406.94% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Work In Process (Yearly) stood at $6.4 million in 2020, then increased by 6.28% to $6.8 million in 2021, then decreased by 27.24% to $4.9 million in 2022, then dropped by 6.01% to $4.6 million in 2023, then skyrocketed by 1,406.94% to $69.7 million in 2024.